A previous study revealed that CD39 can serve as a tumor-specific T-cell marker and that CD39+ CD8+ T cells can predict the response of NSCLC patients to PD-1 or PD-L1 blockade treatment, thus serving as an independent predictive indicator. The gene discussed is CD274; the disease is neoplasm.